Contributed by Chi-Ming Che; received October 6, 2023; accepted April 27, 2024; reviewed by Harry B. Gray and Yi Lu ...

“We are thrilled to bring forward the first phase 3 results from our clinical development program evaluating enlicitide, which, if approved, would be the first marketed oral PCSK9 inhibitor in ...

Merck’s investigational PCSK9 inhibitor enlicitide decanoate significantly lowered low-density lipoprotein cholesterol in patients with abnormally high lipid blood levels in two Phase III readouts, ...

Department of Bioscience, Tokyo University of Agriculture, 1-1-1 Sakuragaoka, Setagaya-ku , Tokyo156-8502, Japan Graduate School of Agricultural and Life Sciences, The University of Tokyo, 1-1-1 Yayoi ...

Bayer’s Vividion Therapeutics has secured the global rights from its partner Roche to the only covalent Werner helicase (WRN) inhibitor to have made it into the clinic. Vividion and Roche have ...

Insilico Medicine and collaborators reported promising safety and efficacy results from a Phase IIa trial of Rentosertib (known as ISM001-055), a TNIK inhibitor developed using Insilico's ...

While the combinations of novel hormone therapies and PARP inhibitors have already shown to improve outcomes in the castrate-resistant setting, this is the first trial to show that the addition of a ...

A novel plant hormone, strigolactone (SL), plays a crucial role in root growth ... The effects of the SL analogue (rac-GR24) and SL inhibitor (TIS108) on the root architecture under low and high Pi ...

SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in the discovery of inhibitors of challenging targets for inflammatory disease, today announced that the company has nominated a ...

Background: Despite the unprecedented advancement of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) in the treatment paradigm for hormone-dependent breast cancer, reports of cardiovascular ...